SCHEMBL4774486

SCHEMBL4774486

Nc1nccc(/C=C/c2c(-c3ccc(F)cc3)nc3sccn23)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 12/20 1.00
KDR P35968 11/20 0.80
FLT1 P17948 10/20 0.80
GRM4 Q14833 2/20 0.50
PRKD3 O94806 1/20 0.49
MAP4K4 O95819 1/20 0.49
FGFR1 P11362 1/20 0.49
FRK P42685 1/20 0.49
MAPK8 P45983 1/20 0.49
MAPK9 P45984 1/20 0.49
CSNK1A1 P48729 1/20 0.49
CSNK1D P48730 1/20 0.49
GSK3B P49841 1/20 0.49
CSNK1G2 P78368 1/20 0.49
PRKCD Q05655 1/20 0.49
ERBB4 Q15303 1/20 0.49
MINK1 Q8N4C8 1/20 0.49
PRKD2 Q9BZL6 1/20 0.49
CSNK1G1 Q9HCP0 1/20 0.49
MAP3K20 Q9NYL2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774488 1.00 TEK (1.00) TEKKDRFLT1GRM4PRKD3
SCHEMBL4771869 0.89 TEK (0.80) TEKKDRFLT1PRKD3MAP4K4
SCHEMBL4774631 0.89 TEK (0.80) TEKKDRFLT1GRM4CHEK2
SCHEMBL4774625 0.89 TEK (0.80) TEKKDRFLT1GRM4CHEK2
SCHEMBL4764574 0.89 TEK (0.80) TEKKDRFLT1GRM4CHEK2
SCHEMBL4764578 0.89 TEK (0.80) TEKKDRFLT1GRM4CHEK2
SCHEMBL4771873 0.89 TEK (0.80) TEKKDRFLT1PRKD3MAP4K4
SCHEMBL4764883 0.89 TEK (1.00) TEKKDRFLT1GRM4
SCHEMBL4764887 0.89 TEK (1.00) TEKKDRFLT1GRM4
SCHEMBL4767246 0.82 TEK (0.74) TEKKDRFLT1GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575963-B1 ANTI-ANGIOGENETIC THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2008-05-07 EP disclosed
US-20060069109-A1 Therapeutic agents ASTRAZENECA AB (SE) 2006-03-30 US disclosed
EP-1575963-A1 THERAPEUTIC AGENTS AstraZeneca AB (SE) 2005-09-21 EP disclosed
WO-2004058776-A1 THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069109-A1 Therapeutic agents TIE1, TEK, KDR TEK 2/4885KDR 3/4885FLT1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.